Pathogenesis and Glycemic Management of Type 2 Diabetes Mellitus: A Physiological Approach

被引:1
|
作者
Ismail-Beigi, Faramarz [1 ,2 ]
机构
[1] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
关键词
beta-cell number; disposition index; glycemic target range; insulin resistance; LIFE-STYLE INTERVENTIONS; NONCOMMUNICABLE DISEASES; SUSCEPTIBILITY LOCI; INSULIN-SECRETION; NATURAL-HISTORY; GLUCOSE CONTROL; FOLLOW-UP; ASSOCIATION; THERAPY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2DM) is an incompletely understood chronic, progressive multifactorial disease with insulin resistance and decreased beta-cell function playing dominant roles in its genesis. The worldwide incidence of the disease is rapidly increasing to pandemic proportions. The increase in incidence of T2DM is attributable to changes in lifestyle, diet and obesity, but other causes remain to be defined. The disease is a major cause of early mortality due to atherosclerosis and cardiovascular disease (CVD), and is the leading cause of blindness, leg amputations, and chronic renal disease. Hyperglycemia inT2DM becomes manifest once insulin secretion is no longer adequate for the metabolic demands of the individual. The approach to glycemic management of the disease is increasingly based on understanding the underlying pathophysiology. Efforts to maintain and preserve beta-cell function during the earlier phases of the disease may have important implications in prevention of subsequent complications of TDM. Finally, the approach to glycemic management of the disease should be individualized by considering the psycho-socio-economic condition of each patient, and glycemic targets should reflect presence of comorbid conditions, age of the patient, the stage of their disease in terms of duration, presence of macro- and micro-vascular complications, and propensity for severe hypoglycemia.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 50 条
  • [1] Glycemic Management of Type 2 Diabetes Mellitus
    Ismail-Beigi, Faramarz
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (14): : 1319 - 1327
  • [2] Glycemic Management of Type 2 Diabetes Mellitus Reply
    Ismail-Beigi, Faramarz
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02): : 183 - 183
  • [3] Bromocriptine Mesylate for Glycemic Management in Type 2 Diabetes Mellitus
    Kerr, Jessica L.
    Timpe, Erin M.
    Petkewicz, Katherine A.
    [J]. ANNALS OF PHARMACOTHERAPY, 2010, 44 (11) : 1777 - 1785
  • [4] Pathogenesis of type 2 diabetes mellitus
    Dostou, J
    Gerich, J
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2001, 109 : S149 - S156
  • [5] Pathogenesis of type 2 diabetes mellitus
    Guillausseau, PJ
    Laloi-Michelin, M
    [J]. REVUE DE MEDECINE INTERNE, 2003, 24 (11): : 730 - 737
  • [6] Pathogenesis of type 2 diabetes mellitus
    Leahy, JL
    [J]. ARCHIVES OF MEDICAL RESEARCH, 2005, 36 (03) : 197 - 209
  • [7] Pathogenesis of type 2 diabetes mellitus
    DeFronzo, RA
    [J]. MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (04) : 787 - +
  • [8] Glycemic Control of Type 2 Diabetes Mellitus
    Fikree, Majeda
    Hanafi, Baderuldeen
    Hussain, Zahra Ali
    Masuadi, Emad M.
    [J]. BAHRAIN MEDICAL BULLETIN, 2006, 28 (03)
  • [9] An integrative approach to the management of type 2 diabetes mellitus
    Kligler, B
    Lynch, D
    [J]. ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE, 2003, 9 (06) : 24 - 32
  • [10] Molecular pathogenesis of type 2 diabetes mellitus
    Kadowaki, T
    [J]. SEIKAGAKU, 1999, 71 (11): : 1281 - 1298